via @brodariousH

Auburn signee Brodarious Hamm, a three-star offensive lineman from Georgia, has been diagnosed with Hodgkin’s lymphoma, a form of cancer. Luckily, Hamm tells Auburn Undercover the prognosis is very good.

Hamm is inconceivably the second recruit in his class to be diagnosed with cancer. Tashawn Manning, a defensive tackle prospect, was diagnosed with a rare form of Leukemia around Thanksgiving. Manning was also given a good prognosis and hopes to enroll at Auburn early next year.

As for Hamm, the incoming freshman said he still hopes to be at Auburn in May, or at least by August. He started chemotherapy two or three weeks ago, and told Auburn Undercover he has managed the treatment well.

“It hasn’t been bad,” he said. “I haven’t lost any weight.”

“I’m feeling pretty good,” he said. “I don’t even feel like anything is wrong with me.”

Head coach Gus Malzahn offered words of support for Hamm when he spoke after Tuesday’s practice.

“Our thoughts and prayers are with him and his family,” Malzahn said. “He’s a fine young man with a fine family. He has a great attitude. … We’re going to be there for him. He’s going to get through this and we expect him to be with us after a short period of time after he gets healthy.”

While not on the team yet, Hamm and Manning could become the second and third Auburn football players in recent years to beat a cancer diagnosis. Former offensive tackle Shon Coleman was diagnosed with acute lymphoblastic leukemia before enrolling at Auburn back in 2010. His battle delayed his start with the Tigers, but Coleman enrolled in school by 2011, and was declared cancer-free in October 2012.

Now, Coleman is a projected first- or second-round pick in the upcoming NFL draft after two stellar seasons anchoring the Tigers offensive line.

Here’s hoping Hamm and Manning find similar results as Coleman.

[College Spun]

About Ben Sieck

Ben is a recent graduate of Butler University where he served as Managing Editor and Co-Editor-in-Chief for the Butler Collegian. He currently resides in Indianapolis.